Marex Group’s CERo Therapeutics CERO Stock Holding History

Marex Group’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8	Closed	-$900	–	876
2024 Q4	$900	Buy	+8	New	+$1.86K	﹤0.01%	676

Other funds holding CERO

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

APP

Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Marex Group's CERO Position: Q1 2025 in Review

Marex Group sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 8 shares — an estimated $900 sold.

Marex Group first reported a position in CERO in Q4 2024 and held it in 1 quarter. The position peaked at $900 in Q4 2024. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

Marex Group reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
Marex Group sold 8 CERo Therapeutics shares in Q1 2025, an estimated $900.
Marex Group first reported a position in CERo Therapeutics in Q4 2024 and held it in 1 quarter.
Marex Group's CERo Therapeutics position peaked at $900 in Q4 2024.
13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on Marex Group's 13F filing for Q1 2025, filed 2 Apr 2026.